In this article, I will highlight companies with successful innovation, promising pipelines, and solid financials while discussing the best biotech stocks to buy.
These stocks are poised to lead in growth in 2025, so if you’re keen on market leaders or fresh market entrants, these stocks will not disappoint. Keep reading to learn about vital picks that stand to radically advance healthcare and yield remarkable investment profits.
Key Points & Best Biotech Stocks To Buy List
| Company Name | Key Point |
|---|---|
| Vertex Pharmaceuticals Incorporated | Known for its breakthrough treatments for cystic fibrosis. |
| Moderna, Inc. | Pioneered mRNA vaccine technology; key player in COVID-19 vaccine rollout. |
| BioNTech SE | German biotech best known for its mRNA COVID-19 vaccine developed with Pfizer. |
| Exelixis, Inc. | Focuses on oncology, especially kidney and liver cancer treatments. |
| Regeneron Pharmaceuticals, Inc. | Developed EYLEA for eye diseases and monoclonal antibodies for COVID-19. |
| Summit Therapeutics, Inc. | Focused on antibiotic innovation and targeted oncology therapies. |
| Axsome Therapeutics, Inc. | Specializes in CNS disorders, with key drugs for depression and migraines. |
| Halozyme Therapeutics, Inc. | Known for its ENHANZE® drug delivery platform enhancing biologic therapies. |
| BioMarin Pharmaceuticals Inc. | Develops therapies for rare genetic diseases, including enzyme replacement. |
| Ascentage Pharma | Chinese biotech focused on apoptosis-targeted cancer and hepatitis B drugs. |
10 Best Biotech Stocks To Buy
1.Vertex Pharmaceuticals Incorporated
Industry experts consider Vertex Pharmaceuticals (NASDAQ: VRTX) to be one of the most industries-ready biotech stock to invest in 2025 due to its impressive financial data and progressive pipeline.
The firm continues to lead in the cystic fibrosis (CF) market, with remedies like Trikafta bringing in more than $10 billion yearly. Vertex’s diversification efforts are apparent with the most recent FDA approvals for Casgevy, a gene-editing therapy for sickle cell disease, and Journavx, a non-opioid pain medication.
With a balanced sheet of $11.2 billion in cash and low debt, Vertex is positioned for growth. Analysts predict 2025 revenues to be between 11.75 – 12 billion suggesting an increased market presence for the firm.
| Feature | Description |
|---|---|
| Focus Areas | Cystic fibrosis treatments, rare diseases |
| Key Drugs | Trikafta, Kalydeco |
| Market Position | Leader in cystic fibrosis therapies |
| Pipeline | Expanding into pain management and gene editing |
| Financial Health | Strong revenue growth with steady R&D investment |
2.Moderna, Inc.
Investors have encountered hurdles as Moderna Inc. (NASDAQ:MRNA) remains a compelling biotech stock in the long-run in 2025.
The firm assumes that through a set target of 2025, revenues would lie within an estimate of 1.5 billion and 2.5 billion which is lower than 3.2 billion for 2024; this is primarily due to dwindling COVID-19 vaccination sales. To counter these issues, Moderna plans to cut costs by $1 billion in 2025 with an additional cut of $500 million in 2026.
Included in Moderna’s strong pipeline are late stage candidates for RSV, cytomegalovirus, and personalized cancer vaccines created in partnership with Merck.
The company expects as much as 10 product approvals by 2027, these could add revenues to help diversify the firm’s matrix. With a sustainable position of cash equals 9.5 billion by the bank at the end of 2024, Moderna is slated towards funding their R&D initiatives.
Short term profits for now seem to be a problem, however, analysts expect the firm to return to profitability by the year 2029.
With the application of their innovative mRNA platform and consideration on focusing strategic targets approach areas of high value proposition, there are significant opportunities for long term growth potential for investors willing to manage the short term bumps.
| Feature | Description |
|---|---|
| Technology Platform | mRNA technology platform |
| Key Products | COVID-19 vaccines, RSV vaccine candidates |
| Pipeline | Personalized cancer vaccines, infectious disease vaccines |
| Financial Position | Robust cash reserves with ongoing cost reductions |
| Growth Potential | Diversifying revenue beyond COVID-19 vaccines |
3.BioNTech SE
BioNTech’s (NASDAQ: BNTX) stock seems like a strong buy heading into 2025 due to its solid oncology pipeline and strong financials.
The company is currently working on a BANT327/PM8002, a bispecific antibody against PD-L1 and VEGF-A; it is in Phase 2/3 trials for non-small cell lung cancer and breast cancer (triple negative).
Besides, BioNTech, in partnership with Genentech, is working on an individualized mRNA cancer vaccine, autogene cevumeran.
Though revenue is anticipated to decline to €1.7 – 2.2 billion in 2025, analysts continue to have a ‘Strong Buy’ consensus, with a 12-month price target estimated at $146.17 which presents potential upside.
| Feature | Description |
|---|---|
| Specialization | mRNA-based immunotherapies and oncology |
| Key Products | COVID-19 vaccines, cancer vaccine candidates |
| Pipeline | Bispecific antibodies, personalized cancer vaccines |
| Strategic Partnerships | Collaboration with Genentech, Pfizer |
| Market Outlook | Strong growth expected despite short-term revenue dips |
4.Exelixis, Inc
Exelixis Inc. (NASDAQ: EXEL) is one of the distinguished biotechs to look out for in 2025 owing to its solid financials and an alluring oncology pipeline.
Its flagship drug, Cabometyx, still yields enormous revenue and is expected to bring in total revenue of somewhere between $2.15-2.25 billion for the year 2025.
Zanzalintinib, Exelixis’ other asset, is also zanzalintinib being tested in several pivotal trials with important data readouts anticipated in the second half of 2025.
With regards to stock evaluation, analysts have a “buy” rating with the 12 months price target averaging at $37.59, showcasing some belief in company growth.
| Feature | Description |
|---|---|
| Therapeutic Focus | Oncology |
| Key Drugs | Cabometyx |
| Pipeline | Zanzalintinib, other targeted therapies |
| Revenue Forecast | Projected steady revenue growth |
| Analyst Ratings | Generally positive “Buy” consensus |
5.Regeneron Pharmaceuticals, Inc
Biotech is one of the sectors that is expected to yield good returns in Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) seems to be one of them as it has strong financials and a promising pipeline.
In , the company’s revenue increased by 8% year on year, reaching $14.2 billion and announcing its first quarterly dividend.
This reflects sustained growth and confidence in the business. Ascendings sales are driven by key products such as Dupixent and EYLEA and linvoseltamab for multiple myeloma and odronextamab for lymphoma add to the company’s growing oncology portfolio.
There is a consensus “Buy” recommendation from analysts with a 12-month price estimate of 907.39 USD, translating to strong potential upside.
| Feature | Description |
|---|---|
| Therapeutic Areas | Immunology, oncology, ophthalmology |
| Key Products | Dupixent, EYLEA |
| Pipeline | New oncology therapies like linvoseltamab, odronextamab |
| Financial Strength | Strong revenue growth and dividend initiation |
| Analyst Outlook | Positive with significant upside potential |
6.Summit Therapeutics, Inc
Summit Therapeutics Inc. SMMT has been identified as a stock to watch for 2025 due to the oncology pipeline and strong market performance.
The company’s lead candidate, ivonescimab, achieved a clinical milestone by demonstrating 49% lower risk of progression in disease compared to Merck’s Keytruda in a late-stage non-small cell lung cancer trial.
This has led to a positive response from analysts with Goldman Sachs raising its price target to $41 and HC Wainwright maintaining a $44 target, signaling strong upside potential.
Although the company continues to face financial headwinds including an annual cash burn of $157 million, Summit’s cash reserves of $412 million offer 2.6 years of runway which supports investment in the company’s promising pipeline.
Summit’s strategic focus on groundbreaking therapies combined with a market cap of $17.79 billion and a share price of $25.77 as of May 23, 2025 makes it an attractive candidate in the biotech sector.
| Feature | Description |
|---|---|
| Focus | Oncology, precision medicine |
| Lead Candidate | Ivonescimab (NSCLC) |
| Clinical Results | 49% reduction in disease progression risk |
| Financials | Cash runway of 2.6 years with ongoing investment |
| Analyst Ratings | Positive price target increases |
7.Axsome Therapeutics, Inc
Axsome Therapeutics Inc. (NASDAQ: AXSM) will emerge as a promising investment opportunity for mid 2025 due to advancements in the Central Nervous System (CNS) therapeutics. For 1Q 2025, the net product revenue was reported to be $121.5 million with an increase of 62% year over year which enabled AUVELITY® to reach 96.2 million dollars in sales with 80% increase.
Under the late stage pipeline, Axsome has AXS-05 for managing agitation in Alzheimer’s patients, AXS-12 for narcolepsy, and AXS-14 for fibromyalgia, with plans for regulatory submission in the year 2025. SYMBRAVO® was also approved by FDA for acute migraine treatment with plans for commercial launch in June 2025.
Analysts set the consensus as Strong Buy with a target of $172.14 for 12 months showing upside of roughly 64% from price of $104.35 currently. With such an impressive product portfolio and ample capital, Axsome will excel throughout the remainder of the biotech growth phase.
| Feature | Description |
|---|---|
| Focus | Central nervous system (CNS) disorders |
| Key Products | AUVELITY®, SYMBRAVO® |
| Pipeline | AXS-05 (Alzheimer’s agitation), AXS-12 (narcolepsy), AXS-14 (fibromyalgia) |
| Recent Performance | 62% revenue growth year-over-year |
| Market Potential | Strong analyst “Strong Buy” consensus |
8.Halozyme Therapeutics, Inc
In 2025, Halozyme Therapeutics Inc. (NASDAQ: HALO) is forecasted to remain one of the most lucrative biotech stocks because of its proprietary ENHANZE® drug delivery system and robust financial results.
The company reported revenue of $264.86 million for Q1 2025, a 35% increase year-over-year, and an adjusted EPS of $1.11 which is a 41% rise. Contributions to growth came from key products such as VYVGART Hytrulo, Phesgo, and Darzalex SC.
Analysts still hold a positive view despite concern from potential CMS draft guidance relating to combination products and regulatory headwinds. The analyst consensus price target is $63.56 which is a considerable upside from the current share price of $53.75.
| Feature | Description |
|---|---|
| Core Technology | ENHANZE® drug delivery platform |
| Key Products | Darzalex SC, Phesgo, VYVGART Hytrulo |
| Financial Performance | 35% revenue growth in Q1 2025 |
| Regulatory Risks | Potential challenges from CMS draft guidance |
| Analyst Consensus | Positive outlook with price target upside |
9.BioMarin Pharmaceuticals Inc
BioMarin Pharmaceuticals Inc. (NASDAQ: BMRN) is one of the leading biotech companies focusing on the development of therapies for rare genetic disorders. During Q1 2025, BIOMARIN reported total revenues of $745 million, which was an increase of 15% from the previous year.
This was driven by exceptional sales of VOXZOGO®, which grew 40% in revenue to $214 million. The company maintained its full-year 2025 revenue guidance of $3.1–$3.2 billion and EPS guidance of $4.20-4.40.
BioMarin’s pipeline consists of four areas with investigational medicines, which are central nervous system, cardiovascular, musculoskeletal/metabolic, and non-oncology hematology.
BioMarin has positioned itself well as this company’s strategic focus on rare diseases coupled with their solid financial performance makes them highly adaptable to continued growth in the sector. BioMarin’s stock price on May 23, 2025, was $58.01, and has a market cap of 11.5 billion.
| Feature | Description |
|---|---|
| Therapeutic Focus | Rare genetic diseases |
| Key Products | VOXZOGO® |
| Revenue Growth | 15% increase year-over-year in Q1 2025 |
| Pipeline | CNS, cardiovascular, musculoskeletal/metabolic, hematology therapies |
| Market Cap | Approx. $11.5 billion as of 2025 |
10.Ascentage Pharma
Ascentage Pharma Group International (NASDAQ: AAPG), a China-based biotech company is drawing interests in 2025 due to ich promising oncology pipeline and strategic global expansion. Ascentage raised $126 million in January 2025 through its U.S.
Initial Public Offering (IPO), which was the first biotech IPO of the year . Their leading candidate, olverembatinib (HQP1351), is a third generation BCR-ABL inhibitor undergoing Phase III trials for chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) .
Also, a BCL-2 inhibitor, lisaftoclax (APG-2575), is in the final stages of testing for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) . These assets have been incorporated into the Chinese Society of Clinical Oncology 2025 guidelines, highlighting their clinical value .
Analysts estimate Ascentage Pharma would be able to turn profitable by 2026 considering the company’s advanced treatments in development and increasing market foothold . As of May 2025, with a share price of $25.12 the company is a strong candidate for investment targeting rapidly growing oncology focused biotech companies .
| Feature | Description |
|---|---|
| Location | China-based biotech company |
| Key Candidates | Olverembatinib (CML, ALL), Lisaftoclax (CLL, SLL) |
| Recent Funding | Raised $126 million in 2025 U.S. IPO |
| Clinical Impact | Included in Chinese Society of Clinical Oncology 2025 guidelines |
| Growth Outlook | Expected profitability by 2026 |
Conclusion
Summarizing, The Best Biotech Stocks To Buy In 2025 generated considerale attention and is likely to grow further with developing therapies, their respective pipelines, projected stemmed from their finances, and is predicted to strengthen in the future.
Established firms like Moderna, Vertex, and Regeneron combine technology with market-proven products, while emerging firms like Summit and Ascentage show promising breakthroughs. Buying these stocks will help capture the rapidly evolving future of biotechnology.
